<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: Canadian Generic Drugmakers Fight Patent Law</title>
	<atom:link href="http://www.pharmalot.com/2008/12/canadian-generic-drugmakers-fight-patent-law/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2008/12/canadian-generic-drugmakers-fight-patent-law/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 22:30:57 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: Pier-Giorgio Fontana</title>
		<link>http://www.pharmalot.com/2008/12/canadian-generic-drugmakers-fight-patent-law/#comment-384856</link>
		<dc:creator>Pier-Giorgio Fontana</dc:creator>
		<pubDate>Tue, 16 Dec 2008 21:04:46 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=18627#comment-384856</guid>
		<description>The article refers to a 20-year patent protection for new pharmaceuticals. It should be clarified that in general research-based pharma companies file for patent when a research compound appears to be pharmacologically active and likely to be successful. By the time all pre- and post-clinical activities are completed, including regulatory filing and Health Authorities' review and approval process, several years are eroded from the 20-years patent life. Thus the actual market exclusivity can be only a small fraction of those 20 years.
Generic companies seem to exploit the public's general ignorance of the complex new drug development process.</description>
		<content:encoded><![CDATA[<p>The article refers to a 20-year patent protection for new pharmaceuticals. It should be clarified that in general research-based pharma companies file for patent when a research compound appears to be pharmacologically active and likely to be successful. By the time all pre- and post-clinical activities are completed, including regulatory filing and Health Authorities&#8217; review and approval process, several years are eroded from the 20-years patent life. Thus the actual market exclusivity can be only a small fraction of those 20 years.<br />
Generic companies seem to exploit the public&#8217;s general ignorance of the complex new drug development process.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Paul</title>
		<link>http://www.pharmalot.com/2008/12/canadian-generic-drugmakers-fight-patent-law/#comment-384809</link>
		<dc:creator>Paul</dc:creator>
		<pubDate>Tue, 16 Dec 2008 15:54:32 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=18627#comment-384809</guid>
		<description>This seems crazy. 8 years already seems very few years in which to recoup R&#38;D costs, and they want it reduced?

Where do the generic companies think they are going to get the products to copy if the name brand companies don't have enough time to recoup investments and therefore will stop discovering.  Very odd.</description>
		<content:encoded><![CDATA[<p>This seems crazy. 8 years already seems very few years in which to recoup R&amp;D costs, and they want it reduced?</p>
<p>Where do the generic companies think they are going to get the products to copy if the name brand companies don&#8217;t have enough time to recoup investments and therefore will stop discovering.  Very odd.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.152 seconds -->

